Anbio Biotechnology (NNNN)
$4.26-3.40%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $187M
- Beta
- 5.26
- P/E (TTM)
- 22.03
- Short % float
- 0.14%
- Days to cover
- 1.0
- SI change
- +4.5%
- 1W
- -13.06%
- 1M
- -30.28%
- vs SPY 1W
- -12.92%
- vs SPY 1M
- -32.78%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 23
- VALUE
- 17
- GROWTH
- 41
- GARP
- 11
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC16.5%
REV YoY-
ROE27.5%
EPS YoY-
ROA28.1%
GROSS86
OP65
NET72
[VALUATION]
P/E TTM22.03
P/E FWD-
SECTOR PE20.34
INDUSTRY PE45.85
P/B6.20
P/FCF-
EV/EBITDA27.67
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO344.31
ND/EBITDA-
BETA5.26
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on NNNN?
- LOPJLB’s latest quantitative signal on Anbio Biotechnology Class A Ordinary Shares (NNNN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NNNN in?
- Anbio Biotechnology Class A Ordinary Shares (NNNN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Anbio Biotechnology Class A Ordinary Shares (NNNN) do?
- Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (bot…